Neoplasms Clinical Trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 1863 clinical trials
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease. Secondary Objective:
- 23 views
- 09 Sep, 2021
- 4 locations
C1071003 MagnetisMM-3
The purpose of the study is to evaluate whether single-agent PF-06863135 can provide clinical benefit in participants with relapsed/refractory multiple myeloma. PF-06863135 is a bispecific antibody: binding of PF-06863135 to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
- 1 views
- 17 Sep, 2021
- 4 locations
ATR Inhibitor BAY 1895344 plus pembrolizumab in advanced solid tumors (GI, Pancreatic, mCRPC, NSCLC)
pembrolizumab, may improve antitumor responses in advanced cancer patients with DDR aberrations, at an acceptable safety profile and an expected positive benefit/risk ratio.
- 1 views
- 14 Sep, 2021
- 10 locations
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (KRYSTAL-10)
Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
- 5 views
- 13 Sep, 2021
- 42 locations
Phase 1 study of BAY1905254 - An early clinical research study to evaluate a new drug called Bapotulimab (BAY1905254) in the expansion cohort in combination with Pembolizumab in Head and Neck cancer that has returned or is discovered to be metastatic and is expressing PDL1.
is safe for the participants, how it affects the body and to try to find the best dose of the new drug to give to participants and to obtain a preliminary assessment of the tumor response efficacy in
- 0 views
- 14 Sep, 2021
- 8 locations
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
- 0 views
- 25 Aug, 2021
- 7 locations
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
innovative therapy for an efficient tumor control and may allow to identify types of cancer or molecular types of cancer that are more receptive to immunotherapy. For all treatments, the second period
- 0 views
- 19 Sep, 2021
- 13 locations
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.
, in novel combinations with anti-cancer agents, to participants with relapsed/refractory haematological malignancies.
- 0 views
- 17 Sep, 2021
- 33 locations
A Study of ASP1951 in Subjects With Advanced Solid Tumors
locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1951 when administered as a single agent and in combination with pembrolizumab; and determine the
- 28 views
- 12 Sep, 2021
- 32 locations
A Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Clinical Activity of JNJ-63723283 an Anti-PD-1 Monoclonal Antibody in Participants With Advanced Cancers
participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), melanoma, renal, bladder, small-cell lung cancer (SCLC), gastric/esophageal cancer, and high-level microsatellite
- 49 views
- 15 Sep, 2021
- 35 locations